ইস্রায়েল - ইংরেজি - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

ইস্রায়েল - ইংরেজি - Ministry of Health

astra zeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapy :faslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women: not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant endocrine therapy; or disease progression on endocrine therapy.combination therapy with palbociclib: faslodex is indicated for the treatment of hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib in women with disease progression after endocrine therapy

ইস্রায়েল - ইংরেজি - Ministry of Health

astrazeneca (israel) ltd - fulvestrant - solution for injection - fulvestrant 250 mg / 5 ml - fulvestrant - fulvestrant - monotherapyfaslodex is indicated for the treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:* not previously treated with endocrine therapy,or* with disease relapse on or after adjuvant endocrine therapy;or* with disease progression on endocrine therapy.combination therapy faslodex is indicated for the treatment of:- hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in men and postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy.- hr- positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy.

কানাডা - ইংরেজি - Health Canada

astrazeneca canada inc - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

actavis uk limited - fulvestrant - solution for injection in pre-filled syringe - 250mg millilitre - anti-estrogens

কানাডা - ইংরেজি - Health Canada

teva canada limited - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

mylan pharmaceuticals ulc - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

sandoz canada incorporated - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

apotex inc - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

accord healthcare inc - fulvestrant - solution - 50mg - fulvestrant 50mg - antineoplastic agents